Testosterone optimization, done properly, is the practice of identifying why a man's testosterone is low, correcting that cause where one exists, and when replacement is genuinely indicated, prescribing the lowest dose of bioidentical testosterone that resolves his symptoms while his labs stay safe, retested every 90 days. What most men actually encounter is very different: a questionnaire, a sale, a starting dose, and a monthly bill that never asks why. This guide explains what the medical version involves, who is a candidate and who is not, what the risks are and how they are managed, and how to tell a clinical program from a peptide counter.
- Testosterone optimization is a diagnostic process first: total and free testosterone, SHBG, LH, FSH, prolactin, estradiol and a metabolic panel come before any prescription.
- Symptoms that bring men in are real and specific: low libido, erectile changes, flat mood and motivation, poor recovery, body composition drift, poor sleep.
- A morning total testosterone below roughly 300 ng/dL with consistent symptoms, confirmed on a second draw, is the conventional threshold for considering therapy, not for starting it automatically.
- Monitoring is not optional: hematocrit, PSA, estradiol and lipids are retested at defined intervals, and dose follows labs rather than vibes.
- Programs that profit from the dose or from the vial have a structural conflict; a flat clinical fee with pharmacy-priced medicine removes it.
The symptoms are real, and so is the skepticism
Men arrive with a specific cluster: libido that quietly vanished, erections that are less reliable than they were, motivation and mood that flattened, strength that leaves despite the same training, sleep that stopped repairing anything, and a belly that grows while everything else shrinks. Often these complaints were waved off with a normal-ish total testosterone and a prescription for something else, or with a lecture about aging. The dismissal is its own clinical failure.
The honest position sits between two bad extremes. The first is the industry that sells testosterone to any man with a pulse, where the drug is the product and the diagnosis is theater. The second is the traditional clinic that treats male hormone health as a complaint not worth measuring. Both fail the same patient. The right standard is the endocrinologist's: measure properly, diagnose properly, and treat only when the picture justifies it.
The panel that comes before any conversation about dose
A serious evaluation runs, at minimum, these markers, and ours runs them inside the quarterly Biomarker Audit alongside the metabolic and cardiovascular work, because hormones and metabolism read each other:
The male hormone evaluation
Why each marker matters
| Marker | What it tells the clinician |
|---|---|
| Total testosterone | The headline number; drawn in the morning, ideally fasted, confirmed on a second day |
| Free testosterone and SHBG | The hormone your tissues can actually use; bound testosterone is not available |
| LH and FSH | Distinguishes primary testicular failure from a hypothalamic or pituitary cause |
| Prolactin | Elevated levels point to a pituitary cause that changes the entire workup |
| Estradiol | Aromatization and balance; too low is as symptomatic as too high |
| Hematocrit and PSA | Baseline safety markers before any prescription is considered |
| HbA1c, ApoB, hs-CRP, thyroid | The metabolic and inflammatory context that produces and is produced by low testosterone |
Two practical notes matter. First, a single afternoon draw proves very little; testosterone peaks in the morning and a borderline result needs confirmation on a second morning. Second, low testosterone is frequently the messenger rather than the disease. Obesity, untreated sleep apnea, uncontrolled diabetes, chronic opioid use and heavy alcohol intake all suppress it, and each of those has a treatment that may restore levels without a prescription. Treating the messenger while ignoring the cause is the kind of care a quarterly full panel makes obvious.
Who is a candidate, and who is not
The conventional threshold for considering therapy is a morning total testosterone below roughly 300 ng/dL, confirmed on a repeat draw, in a man with consistent symptoms, after reversible causes have been addressed. Inside that frame there is real judgment: a symptomatic man at 320 with two confirmed draws and a clear cause excluded may be a better candidate than an asymptomatic man at 290. What the frame does not include is a man whose only symptom is that an ad told him he has low T, or a bodybuilder seeking supraphysiological levels, which we do not provide.
Relative contraindications are real and worth stating plainly: active prostate or breast cancer, a markedly elevated hematocrit, untreated severe sleep apnea, and active desire for fertility in the near term, because exogenous testosterone suppresses sperm production and fertility requires a different protocol. A clinician who never says no is not optimizing anything.
What treatment and monitoring actually look like
When therapy is indicated, our protocols use bioidentical testosterone, and the starting point is deliberately conservative. The goal is the lowest dose that resolves symptoms and keeps the safety labs in range, which is the same dose-minimization philosophy we apply to GLP-1s. Follow-up is structured: symptoms and hematocrit are checked early after initiation, and the full panel is repeated at the 90-day audit, where the dose conversation happens against trend data rather than a single value.
The monitoring that protects you is concrete. Hematocrit can climb on therapy and thickened blood carries real risk, so it is tracked and the dose is adjusted when it rises. PSA is followed against baseline. Estradiol is watched because aromatization varies widely between men and both extremes are symptomatic. Lipids and blood pressure are tracked because cardiovascular context is inseparable from hormone therapy. Any program that prescribes without this loop is not managing your health; it is fulfilling an order.
Ask what specific result, on which lab, would make them lower your dose. A clinical program answers with a number. A counter has no answer, because nobody there earns anything from lowering one.
How to spot the med spa version
The pattern is recognizable once you have seen it. A low-cost consult or a free quiz, a same-week prescription before any comprehensive panel, a monthly price that bundles the vial and the injection supplies, testosterone pinned to a marketing-friendly level regardless of symptoms, estradiol blockers sold routinely, and no mention of hematocrit, PSA, or fertility. Some of these operations have drifted further, into peptide stacks and semaglutide-adjacent add-ons with the same quality problems. The common thread is a revenue model that requires you to stay on a product.
Our model is the opposite by construction. The membership is one flat $299 per month, and medication is billed separately by the pharmacy at pharmacy cost with zero markup, so nothing we do changes what we earn from the clinical side. We make money when you get healthier, not when your dose gets stronger.
Testosterone and the cardiometabolic system
We keep returning to one idea across this library: weight, blood sugar, lipids, inflammation and hormones are one interconnected system, and testosterone sits in the middle of it rather than beside it. Low testosterone and metabolic dysfunction feed each other in both directions. Insulin resistance and visceral fat lower testosterone, largely through effects on the hypothalamic signal and on SHBG. Low testosterone in turn promotes fat gain, reduces lean mass, worsens insulin sensitivity and saps the motivation and energy that make training and nutrition stick. Whichever arrow started the loop, the patient experiences it as one story: a softer body, a flatter mood, and labs that drift worse every year.
This is why we never read a testosterone result on its own. The same quarterly Biomarker Audit that carries the hormone panel also carries HbA1c and insulin markers, ApoB, Lp(a), hs-CRP and a full thyroid panel. In practice the reading changes management in both directions. A man whose testosterone sits at 310 with an A1c of 6.1 and elevated hs-CRP is a different patient from a man at 310 with pristine metabolic markers, and often the highest-yield intervention for the first man is metabolic rather than hormonal. Conversely, a patient whose metabolic picture is strong but whose symptoms and confirmed low levels justify therapy can start testosterone knowing his risk layers are already clean.
The practical consequence is concrete. Weight loss raises testosterone on its own, which means a man who loses twenty pounds on a supervised protocol may no longer meet criteria for therapy by the next audit, and that is a success rather than a lost sale. The structure of the fee makes that outcome welcome instead of threatening, because the membership never changes with the prescription and nobody here earns a dollar from the vial.
What it costs, stated plainly
Membership is one flat $299 per month for the clinical layer: the quarterly Biomarker Audit with the full hormone and thyroid panels, the clinician who reads it and answers between visits, and the written protocol. The first charge at checkout is $598, which covers the first two months together: the clinical intake, the first comprehensive panel, and the second month of care while your protocol is built. From month three it is $299 per month, month to month, and you can cancel anytime after the initial commitment.
If therapy is indicated, the testosterone itself is a separate charge, billed by the pharmacy at pharmacy cost, with no markup and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols.
If you have been carrying these symptoms past a normal-ish lab result, start with the eligibility assessment or read our guide to bioidentical hormone therapy. The evaluation costs you one panel and one honest conversation, and it either finds something treatable or tells you plainly that your symptoms have another cause worth chasing.
FAQ
What testosterone level counts as low? The conventional threshold for considering therapy is a morning total testosterone below roughly 300 ng/dL, confirmed on a second morning draw, in a man with consistent symptoms and after reversible causes have been addressed. The number alone never decides; symptoms and context do.
What labs should be done before starting testosterone? Total and free testosterone with SHBG, LH, FSH, prolactin and estradiol, plus baseline hematocrit and PSA, and a metabolic panel including HbA1c, ApoB and hs-CRP. A program that prescribes from a single afternoon testosterone result is guessing.
Does testosterone therapy cause prostate cancer? The evidence does not show that therapeutic testosterone causes prostate cancer, but PSA is monitored on therapy because existing prostate conditions require caution and active prostate cancer is a contraindication. Monitoring is the safeguard that makes therapy responsible.
Can low testosterone be fixed without medication? Sometimes. Weight loss, treatment of sleep apnea, alcohol reduction, correcting opioid use and improving insulin resistance all raise testosterone, sometimes into the normal range. That is why the metabolic panel comes first and therapy is a decision, not a default.
How often should testosterone levels be checked on therapy? Early after initiation and then against a full panel every 90 days, alongside hematocrit, PSA and estradiol. Dose changes are made against trend data, never a single value.
Does testosterone therapy affect fertility? Yes. Exogenous testosterone suppresses sperm production. Men who want children in the near term need a different protocol, which is exactly the kind of conversation a diagnosis-first program has before prescribing.
Related guides
- Bioidentical hormone therapy explained
- Cardiometabolic optimization: the definitive guide
- Hormone optimization at GoodLife Health
- Biomarker audits vs standard blood tests
References
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. pubmed.ncbi.nlm.nih.gov/29562364/
- Urology Care Foundation: Low Testosterone patient resource. 2024. www.urologyhealth.org/urology-a-z/low-testosterone